Rsf-1 在鼻咽癌组织中的表达及与化疗敏感性和预后的关系

The relationship of Rsf-1 expression with chemotherapy sensitivity and prognosis in patients with nasopharyngeal carcinoma

摘要:

目的 探讨Rsf-1在鼻咽癌组织中的表达及与化疗敏感性和预后的关系。方法 选取2015年3月— 2017年8月山东第一医科大学附属济南市人民医院收治的96例鼻咽癌患者的癌组织标本，选取同期该院40例鼻咽 部慢性炎症组织标本作为对照。采用免疫组织化学法检测鼻咽癌组织和鼻咽部慢性炎症组织中Rsf-1的表达， ATP生物荧光抗癌药物敏感性检测技术检测96例鼻咽癌组织细胞对8种化疗药（氟尿嘧啶、顺铂、卡铂、奥沙利 铂、紫杉醇、多西他赛、吉西他滨、环磷酰胺）的敏感性。根据免疫组织化学结果将鼻咽癌患者分为高表达组和 低表达组，比较两组临床病理特征、化疗药耐药率和生存预后。结果 鼻咽癌组织中Rsf-1高表达率为66.67% （64/96）高于慢性炎症组织的7.50%（3/40）（P <0.05）。T3期、T4期患者Rsf-1 高表达率高于T1期、T2期患者 （P <0.05）。多西他赛、吉西他滨耐药率均高于氟尿嘧啶、顺铂、卡铂、奥沙利铂、紫杉醇、环磷酰胺（P < 0.05）。高表达组的紫杉醇耐药率高于低表达组（P <0.05）。多因素Cox 回归分析结果显示，鼻咽癌M 分 期［H^R=3.004（95% CI：1.674，6.143）］、临床分期［H^R=3.189（95% CI：2.089，4.431）］和Rsf-1［H^R=3.305， （95% CI：2.256，4.897）］是鼻咽癌患者总体生存时间的独立影响因素（P <0.05）。高表达组总体生存时间低于低 表达组（P <0.05）。结论 Rsf-1在鼻咽癌组织中高表达，并且与紫杉醇耐药及患者不良生存预后有关。

Abstract:

Objective To investigate the expression of remodeling and spacing factor 1 (Rsf-1) in nasopharyngeal carcinoma tissue and its relationship with chemotherapy sensitivity and prognosis. Methods We selected 96 cases of nasopharyngeal carcinoma tissues from the patients admitted to our hospital from March 2015 to August 2017, and collected 40 cases of chronic nasopharyngeal inflammation tissues at the same period as the control. The expression of Rsf-1 in these tissues was detected by immunohistochemistry. The adenosine triphosphatebased bioluminescence tumor chemosensitivity assay (ATP-TCA) was used to detect the sensitivity of the nasopharyngeal carcinoma cells to 8 chemotherapeutic drugs (fluorouracil, cisplatin, carboplatin, oxaliplatin, paclitaxel, docetaxel, gemcitabine, and cyclophosphamide). According to the results of immunohistochemistry, nasopharyngeal carcinoma patients were divided into high-expression group and low-expression group, and the clinicopathological characteristics, drug resistance rate and prognosis of the two groups were compared. Results The expression rate of Rsf-1 in nasopharyngeal carcinoma tissues was 66.67% (64/96), which was significantly higher than that in chronic nasopharyngeal inflammation tissues (7.50%) (3/40) (P < 0.05). The expression rate of Rsf-1 in T3 and T4 stage patients was higher than that in T1 and T2 stage patients (P < 0.05). The rates of docetaxel and gemcitabine resistance were higher than those of fluorouracil, cisplatin, carboplatin, oxaliplatin, paclitaxel, and cyclophosphamide resistance (P < 0.05). The rate of paclitaxel resistance in the high-expression group was significantly higher than that in the low-expression group (P < 0.05). Multivariate Cox regression analysis showed that M stage of nasopharyngeal carcinoma [H^R = 3.004 (95% CI: 1.674, 6.143)], clinical stage [H^R = 3.189 (95% CI: 2.089, 4.431)] and Rsf-1 expression [H^R = 3.305 (95% CI: 2.256, 4.897)] were independent factors influencing the overall survival time of nasopharyngeal carcinoma patients (P < 0.05). The overall survival time of high-expression group was significantly lower than that of low-expression group (P < 0.05). Conclusions Rsf-1 is highly expressed in nasopharyngeal carcinoma, and is related to paclitaxel resistance and poor survival prognosis in nasopharyngeal carcinoma patients.